公开(公告)号：US20210113537A1

公开(公告)日：2021-04-22

申请号：US16493931

申请日：2018-03-16

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Craig D. KARR ,  Manav KORPAL ,  Nathalie RIOUX ,  Peter Gerard SMITH

IPC: A61K31/445 ,  A61K31/519 ,  A61K45/06 ,  A61P35/00

Abstract: Provided herein is a combination therapy useful for the treatment breast cancer. The combination comprises an ER-alpha inhibitor and a CDK 4/6 inhibitor.

公开(公告)号：US20180141913A1

公开(公告)日：2018-05-24

申请号：US15821367

申请日：2017-11-22

Applicant: EISAI R & D MANAGEMENT CO., LTD.

Inventor： Mark BOCK ,  Ming-Hong HAO ,  Manav KORPAL ,  Vijay Kumar NYAVANANDI ,  Xiaoling PUYANG ,  Susanta SAMAJDAR ,  Peter Gerard SMITH ,  John WANG ,  Guo Zhu ZHENG ,  Ping ZHU ,  Lorna Helen MITCHELL ,  Nicholas LARSEN ,  Nathalie RIOUX ,  Sudeep PRAJAPATI ,  Dominic REYNOLDS ,  Morgan O'SHEA ,  Thiwanka SAMARAKOON

IPC: C07D231/56 ,  C07D401/14 ,  C07D401/10 ,  C07D413/12 ,  C07D413/14 ,  A61P35/00

CPC classification number: C07D231/56 ,  A61P35/00 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D403/12 ,  C07D413/12 ,  C07D413/14

Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.